Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

EMN 2018 | New antibody treatments for AL amyloidosis

Giampaolo Merlini • 4 May 2018
EMN 2018
Amyloidosis Rare Diseases Antibodies NEOD001
VITAL

This is an exciting time for the treatment of amyloid light-chain (AL) amyloidosis, with a number of novel therapies on the horizon. In this interview, Giampaolo Merlini, MD, from the University of Pavia, Paiva, Italy, discusses the novel agents currently in clinical trials, which can target the amyloid deposits characterizing the disease. Dr Merlini highlights NEOD001 (Phase III VITAL study; NCT02312206) and the combination of CPHPC and anti-serum amyloid P component antibodies (NCT01777243). This video was recorded at the 1st European Myeloma Network Meeting (EMN), in Turin, Italy.

More from Giampaolo Merlini

2:18
The potential of CAR-T therapy for the treatment of amyloidosis
Giampaolo Merlini • 10 May 2022
5:57
Treatment approaches for amyloidosis patients with advanced cardiac involvement
Giampaolo Merlini • 10 May 2022
3:23
Novel agents and clinical trials emerging for the treatment of AL amyloidosis
Giampaolo Merlini • 10 May 2022
3:33
Advances in AL amyloidosis
Giampaolo Merlini • 10 May 2022

Related Videos

0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:59
The common clinical manifestations of BPDCN
Anthony Stein • 15 Apr 2024
3:23
Molecular characteristics associated with increased risk of disease progression in SMM
Mark Bustoros • 27 Sep 2023
2:25
Biomarkers of progression and risk stratification in asymptomatic Waldenström's macroglobulinemia
Mark Bustoros • 27 Sep 2023
The content of VJHemOnc is intended for healthcare professionals